Swedish Adjustable Gastric Banding Observational Cohort Study
Launched by ETHICON ENDO-SURGERY (EUROPE) GMBH · Aug 17, 2010
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Longitudinal prospective cohort study of patients treated consecutively by SAGB in a sample of centers representative of this activity in France.
The study is originated in collaboration with HAS in France and has a target of 500 patients treated with gastric banding because of morbid obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • morbidly obese patients (BMI\>35 with comorbidities or BMI\>40 without comorbidities) in France selected for gastric banding based on standard local clinical practice
- Exclusion Criteria:
- • lower BMI, contraindications based on local clinical assessment
About Ethicon Endo Surgery (Europe) Gmbh
Ethicon Endo-Surgery (Europe) GmbH is a leading global medical device company specializing in advanced surgical solutions, particularly in minimally invasive surgical technologies. As a subsidiary of Johnson & Johnson, the organization focuses on developing innovative products and techniques that enhance surgical efficiency and improve patient outcomes across various medical disciplines. With a commitment to clinical excellence and safety, Ethicon Endo-Surgery actively engages in clinical trials to evaluate the effectiveness of its devices and procedures, contributing to the advancement of surgical practices and the overall health care landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rillieux La Pape, , France
Patients applied
Trial Officials
Goran Ribaric, MD,MSC,PhD
Study Director
Ethicon Endo-Surgery (Europe) GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials